专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO1997007212A1 OPIOID ANTAGONISTS AND METHODS OF THEIR USE 审中-公开
标题翻译： OPIOI ANTAGONISTS及其使用方法
公开(公告)号：WO1997007212A1
公开(公告)日：1997-02-27
申请号：PCT/US1996013305
申请日：1996-08-12
申请人： OREGON HEALTH SCIENCES UNIVERSITY
发明人： OREGON HEALTH SCIENCES UNIVERSITY , GRISEL, Judith, E. , MOGIL, Jeffrey, S. , GRANDY, David, K. , BUNZOW, James, R. , CIVELLI, Olivier , REINSCHEID, Rainer, Klaus , NOTHACKER, Hans-Peter , MONSMA, Frederick, James
IPC分类号： C12N15/12
CPC分类号： C07K14/665 , A61K38/00
摘要： The present invention relates to a novel mammalian anti-opioid receptor protein (OFQR), peptide ligands (such as OFQ) that bind to OFQR, and methods of using the OFQ peptide and analogues to reverse the physiologic effects of opiates such as morphine. The isolation, characterization and pharmacological use of the endogenous peptide ligand is described. A particular embodiment of the OFQ peptide is a heptadecapeptide having an FGGF aminoterminal motif. The peptide specifically binds to an OFQ receptor protein heterologously expressed in mammalian cells. The peptide does not bind with high affinity to mu , delta or kappa receptors, but it antagonizes opioid mediated effects (such as analgesia and hypothermia) without increasing nociceptive sensitivity. Tyrosine substitution variants of the peptide ligand specifically bind to the opioid receptor and can be radioiodinated. Also provided are methods of making such peptide ligands and OFQR antagonists, and methods of using the ligands for diagnostic and therapeutic uses and for the identification of other naturally-occurring or synthetic opioid receptor ligands.
摘要翻译：本发明涉及新型哺乳动物抗阿片类受体蛋白（OFQR），与OFQR结合的肽配体（如OFQ），以及使用OFQ肽和类似物逆转阿片剂如吗啡的生理作用的方法。描述了内源肽配体的分离，表征和药理学应用。 OFQ肽的具体实施方案是具有FGGF氨基末端基序的十七肽。该肽特异性结合在哺乳动物细胞中异源表达的OFQ受体蛋白。肽不能以高亲和力结合mu，δ或κ受体，但是它不会增加伤害敏感性，而是拮抗阿片样物质介导的作用（如镇痛和低体温）。肽配体的酪氨酸取代变体与阿片受体特异性结合，可以放射性碘化。还提供了制备这种肽配体和OFQR拮抗剂的方法，以及使用该配体进行诊断和治疗用途以及鉴定其它天然存在或合成的阿片受体配体的方法。

12. 发明申请

WO1997000315A1 MITOGEN-ACTIVATED PROTEIN KINASE PHOSPHATASE cDNAs AND THEIR BIOLOGICALLY ACTIVE EXPRESSION PRODUCTS 审中-公开
标题翻译：激活蛋白激酶磷酸化酶cDNA及其生物活性表达产物
公开(公告)号：WO1997000315A1
公开(公告)日：1997-01-03
申请号：PCT/US1996010402
申请日：1996-06-14
申请人： OREGON HEALTH SCIENCES UNIVERSITY , STORK, Philip, J., S. , MISRA-PRESS, Anita
发明人： OREGON HEALTH SCIENCES UNIVERSITY
IPC分类号： C12N09/00
CPC分类号： C12N9/16 , A61K38/00
摘要： The invention relates to a novel mitogen-activated protein kinase phosphatase, MKP-2. The invention further relates to methods and means for preparing and to nucleic acids encoding this protein. The MKP-2 of the present invention is useful in the control of cell growth, differentiation and apoptosis.
摘要翻译：本发明涉及新型丝裂原活化蛋白激酶磷酸酶MKP-2。本发明还涉及编码该蛋白质的核酸的方法和方法。本发明的MKP-2可用于控制细胞生长，分化和凋亡。

13. 发明申请

WO1996004288A1 GLYCINE RECEPTOR ANTAGONIST PHARMACOPHORE 审中-公开
标题翻译：甘氨酸受体拮抗剂药物
公开(公告)号：WO1996004288A1
公开(公告)日：1996-02-15
申请号：PCT/US1995009245
申请日：1995-07-21
申请人： STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON , ACEA PHARMACEUTICALS, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON , ACEA PHARMACEUTICALS, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , CAI, Sui, Xiong , KEANA, John, F., W. , WEBER, Eckard
IPC分类号： C07F05/02
CPC分类号： C07D215/227 , A61K31/404 , A61K31/4184 , A61K31/47 , A61K31/4704 , A61K31/498 , A61K31/5025 , A61K31/517 , A61K31/536 , A61K31/538 , A61K31/55 , A61K31/551 , A61K31/553 , C07B59/002 , C07D209/34 , C07D209/38 , C07D215/22 , C07D215/38 , C07D223/16 , C07D235/26 , C07D235/28 , C07D241/38 , C07D241/44 , C07D241/52 , C07D243/24 , C07D245/06 , C07D265/26 , C07D265/36 , C07F5/02 , C07F5/025
摘要： Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotropic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions and inducing anesthesia are disclosed by administering to an animal in need of such treatment a compound which has high binding to the glycine receptor.
摘要翻译：治疗或预防与中风，局部缺血，CNS创伤，低血糖和手术相关的神经元损失以及治疗神经变性疾病包括阿尔茨海默病，肌萎缩性侧索硬化，亨廷顿病和唐氏综合征的治疗或预防方法，治疗或预防多动症的不良后果通过向需要这种治疗的动物施用与甘氨酸受体具有高结合性的化合物来公开兴奋性氨基酸以及治疗焦虑症，慢性疼痛，抽搐和诱导麻醉。

14. 发明申请

WO1995032002A1 COVALENT MICROPARTICLE-DRUG CONJUGATES FOR BIOLOGICAL TARGETING 审中-公开
标题翻译：生物指标的共同微生物药物联合
公开(公告)号：WO1995032002A1
公开(公告)日：1995-11-30
申请号：PCT/US1995006180
申请日：1995-05-17
申请人： STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY
发明人： STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY , YATVIN, Milton, B. , STOWELL, Michael, H., B. , GALLICCHIO, Vincent, S. , MEREDITH, Michael, J.
IPC分类号： A61K47/48
CPC分类号： A61K9/167 , A61K47/543 , A61K47/544 , A61K47/645 , A61K47/6929 , B82Y5/00 , C07H19/06 , C07H19/10 , Y10S530/811 , Y10S530/813 , Y10S530/814 , Y10S530/815
摘要： This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the targeted of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the target drug is only released in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs covalently linked both to a microparticle via an organic linker molecule and to a polar lipid compound, to facilitate targeting of such drugs to particular subcellular organelles within the cell. Also provided are porous microparticles impregnated with antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combatting and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.
摘要翻译：本发明提供用于特异性递送生物活性化合物给吞噬哺乳动物细胞的新方法和试剂。本发明还涉及通过吞噬细胞对这些生物活性化合物的特异性吸收并且将这些化合物递送到细胞内的特定位点。本发明具体涉及促进抗菌药物和其它试剂进入吞噬细胞并将这些化合物靶向细胞内的特定细胞器的方法。本发明具体提供了这种组合物的组合物和药物实施方案，其包含这种抗微生物药物的共轭物和共价连接到通常称为微粒的颗粒载体的试剂。在具体实施方案中，抗微生物药物通过有机连接分子与微粒共价连接，有机连接分子是具有酶活性的微生物特异性蛋白质的靶向物。因此，本发明提供药物的细胞靶向，其中目标药物仅在感染特定微生物的细胞中释放。这种特定药物递送组合物的替代实施方案还含有有效实现受感染吞噬细胞哺乳动物细胞中细胞内细胞器靶向的极性脂质载体分子。这种缀合物的具体实施方案包括通过有机连接分子与极性脂质化合物共价连接到微粒上的抗微生物药物，以促进将这些药物靶向细胞内的特定亚细胞器官细胞器。还提供了浸渍有抗微生物药物和试剂的多孔微粒，其中微粒的表面或外部程度被在受感染的吞噬细胞哺乳动物细胞内特异性降解的可降解涂层覆盖。还提供了在体内和体外抑制，减弱，阻止，拮抗和克服吞噬哺乳动物细胞的微生物感染的方法。

15. 发明申请

WO1995011972A1 B1k CHAIN OF LAMININ AND METHODS OF USE 审中-公开
标题翻译： B1K LAMININ链和使用方法
公开(公告)号：WO1995011972A1
公开(公告)日：1995-05-04
申请号：PCT/US1994012266
申请日：1994-10-26
申请人： THE GENERAL HOSPITAL CORPORATION , THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON HEALTH SCIENCES UNIVERSITY
发明人： THE GENERAL HOSPITAL CORPORATION , THE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON HEALTH SCIENCES UNIVERSITY , BURGESON, Robert, E. , WAGMAN, David, Wolfe
IPC分类号： C12N15/11
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/00 , C07K14/78
摘要： Recombinant laminin B1k and fragments thereof are produced. The recombinant laminin B1k is a subunit of kalinin a basement membrane protein useful for promoting adhesion of keratinocytes to a substrate and treatment of disorders of the dermis.
摘要翻译：制备重组层粘连蛋白B1k及其片段。重组层粘连蛋白B1k是可用于促进角质形成细胞与底物粘附和治疗真皮病症的基底膜蛋白质的亚基。

17. 发明申请

WO1994016073A2 METHODS AND REAGENTS FOR INHIBITING FURIN ENDOPROTEASE 审中-公开
标题翻译：抑制蛋白内切酶的方法和试剂
公开(公告)号：WO1994016073A2
公开(公告)日：1994-07-21
申请号：PCT/US1994000247
申请日：1994-01-07
申请人： STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY , THOMAS, Gary , ANDERSON, Eric, D. , THOMAS, Laurel , HAYFLICK, Joel, S. , NELSON, Jay , STENGLEN, Stephan, G.
发明人： STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY
IPC分类号： C12N15/15
CPC分类号： C07K14/8107 , A61K38/00
摘要： This invention relates to methods and reagents for inhibiting furin endoprotease activity and specifically for inhibiting furin endoprotease-mediated maturation of bioactive proteins in vivo and in vitro. The invention specifically provides proteins capable of inhibiting furin endoprotease activity. Particularly provided are alpha 1-antitrypsin variants that specifically inhibit furin endoprotease activity. Methods for using furin endoprotease inhibition to attenuate or prevent viral protein maturation, and thereby alleviate viral infections, are provided. Also provided are methods for using furin endoprotease inhibition to attenuate or prevent proteolytic processing of bacterial toxins, thereby alleviating bacterial infections. Methods are also provided to inhibit proteolytic processing of biologically active proteins and peptides. The invention also provides pharmaceutically acceptable compositions of therapeutically effective amounts of furin endoprotease inhibitors.
摘要翻译：本发明涉及用于抑制弗林蛋白酶内切蛋白酶活性的方法和试剂，并且具体用于在体内和体外抑制弗林蛋白酶内切蛋白酶介导的生物活性蛋白质的成熟。本发明特别提供能够抑制弗林蛋白酶内切蛋白酶活性的蛋白质。特别提供了特异性抑制弗林蛋白酶内切蛋白酶活性的α1-抗胰蛋白酶变体。提供了使用弗林蛋白酶内蛋白酶抑制来减弱或预防病毒蛋白质成熟并由此减轻病毒感染的方法。还提供了使用弗林蛋白蛋白内切蛋白酶抑制来减弱或防止细菌毒素的蛋白水解加工的方法，从而减轻细菌感染。还提供了抑制生物活性蛋白质和肽的蛋白水解加工的方法。本发明还提供治疗有效量的弗林蛋白酶内切蛋白酶抑制剂的药学上可接受的组合物。

18. 发明申请

WO1994008013A1 PILIN VARIANTS AND USES THEREOF 审中-公开
标题翻译： PILIN变体及其用途
公开(公告)号：WO1994008013A1
公开(公告)日：1994-04-14
申请号：PCT/US1993009575
申请日：1993-10-07
申请人： STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION on behalf of the OREGON HEALTH SCIENCES UNIVERSITY
发明人： STATE OF OREGON, acting by and through the OREGON STATE BOARD OF HIGHER EDUCATION on behalf of the OREGON HEALTH SCIENCES UNIVERSITY , SO, Magdalene, Y., H. , NASSIF, Zavier
IPC分类号： C12N15/31
CPC分类号： C07K14/22 , A61K38/00 , A61K39/00
摘要： Disclosed are purified polypeptides which, when expressed on the surface of a first cell, enable the first cell to adhere to second cell, the second cell being a human epithelial or endothelial cell, and the polypeptide consisting essentially of the variable region of (Neisseria meningitidis) pilin. Also disclosed are vaccines including these polypeptides, DNA molecules encoding these polypeptides, antibodies which react with these polypeptides, and methods of using these polypeptides, DNAs, antibodies, and vaccines.
摘要翻译：公开了纯化的多肽，当在第一细胞的表面上表达时，其能够使第一细胞粘附到第二细胞，第二细胞是人上皮细胞或内皮细胞，并且所述多肽基本上由脑膜炎奈米氏球菌）皮林还公开了包括这些多肽的疫苗，编码这些多肽的DNA分子，与这些多肽反应的抗体，以及使用这些多肽，DNA，抗体和疫苗的方法。

19. 发明申请

WO1987006463A1 A COMPOSITION HAVING REDUCED NEPHROTOXICITY COMPRISING A FATTY ACID CONTAINING COMPONENT AND CYCLOSPORINE 审中-公开
标题翻译：具有包含含脂肪酸组分和环磷酰胺的降低的抗坏血酸的组合物
公开(公告)号：WO1987006463A1
公开(公告)日：1987-11-05
申请号：PCT/US1987001024
申请日：1987-05-04
申请人： BRIGHAM AND WOMEN'S HOSPITAL , OREGON HEALTH SCIENCES UNIVERSITY , KELLEY, Vicki, E. , BENNETT, William, M.
发明人： BRIGHAM AND WOMEN'S HOSPITAL , OREGON HEALTH SCIENCES UNIVERSITY
IPC分类号： A61K31/20
CPC分类号： A61K35/60 , A61K31/20 , A61K38/13 , A61K2300/00
摘要： Compositions comprising cyclosporine in combination with a vehicle comprising a fatty acid component comprising a fatty acid of the omega-3 or a pharmacologically acceptable salt thereof. Methods for mediating the nephrotoxic effect of cyclosporine and for reducing cyclosporine induced renal prostaglandins comprising administering said cyclosporine in combination with said fatty acid component or a pharmacologically acceptable salt thereof. Eicosapentaenoic acid and docosahexanoic acid are preferred omega-3 fatty acids of the present invention. The compositions and methods of the present invention are useful in clinical and preclinical therapeutic cyclosporine treatment of animals, including humans.
摘要翻译：包含环孢菌素与包含脂肪酸组分的载体的组合物，所述脂肪酸组分包含ω-3的脂肪酸或其药理学上可接受的盐。介导环孢菌素和减少环孢菌素诱导的肾前列腺素的肾毒性作用的方法，包括与所述脂肪酸组分或其药理学上可接受的盐组合施用所述环孢菌素。二十碳五烯酸和二十二碳六烯酸是本发明优选的ω-3脂肪酸。本发明的组合物和方法可用于包括人在内的动物的临床和临床前治疗环孢菌素治疗。

20. 发明申请

WO2022120216A1 COMPOSITIONS AND METHODS FOR DIAGNOSING SARS-COV-2 (COVID-19) AND FOR MONITORING SARS-COV-2-SPECIFIC IMMUNOLOGICAL MEMORY 审中-公开
公开(公告)号：WO2022120216A1
公开(公告)日：2022-06-09
申请号：PCT/US2021/061875
申请日：2021-12-03
申请人： QIAGEN SCIENCES LLC , OREGON HEALTH & SCIENCES UNIVERSITY (OHSU)
发明人： BOYLE, Jeff , HOWARD, Jenny , JAGANATHAN, Soumya , LEWINSOHN, Dave , LEWINSOHN, Deborah , SWARBRICK, Gwendolyn
IPC分类号： G01N33/50 , C07K7/04 , C12Q1/6888 , G01N33/569
摘要： Compositions and methods are provided for detection, diagnosis and prognosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) and for characterization of SARS-CoV-2 antigen-specific T-cell immune responsiveness in COVID-19 patient samples, including in secondary in vitro immune response assays for long-lived anamnestic (memory) T-cell responses. Disclosed compositions and methods include a method that comprises contacting, in vitro, whole blood samples from subjects suspected of having COVID-19 or who have previously been exposed to SARS-CoV-2, with synthetic peptides comprising T-cell epitope-containing regions derived from SARS-CoV-2 Spike proteins; and indirectly detecting SARS-CoV-2-specific activated T-cells by determining production of a T-cell immune response indicator (e.g., interferon-γ) in response to stimulation by the Spike protein-derived peptides.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式